ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Chicago, IL, USA:

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Park Ridge, Illinois, United States and 227 other locations

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Chicago, Illinois, United States and 44 other locations

of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma...

Enrolling
Melanoma (Skin)
Metastatic Melanoma
Drug: Ipilimumab
Drug: Pembrolizumab

Phase 1, Phase 2

Anaveon

Chicago, Illinois, United States and 24 other locations

efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...

Enrolling
Ocular Melanoma
Choroidal Melanoma
Device: Suprachoroidal Microinjector
Drug: Sham Treatment

Phase 3

Aura Biosciences
Aura Biosciences

Chicago, Illinois, United States and 45 other locations

To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...

Active, not recruiting
Uveal Melanoma
Biological: IMCgp100
Biological: Pembrolizumab

Phase 2

Immunocore
Immunocore

Chicago, Illinois, United States and 55 other locations

A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibit...

Active, not recruiting
Melanoma
Biological: Lerapolturev
Biological: Anti-PD-1 Checkpoint Inhibitor

Phase 2

Istari Oncology

Chicago, Illinois, United States and 11 other locations

treatment (pembrolizumab) in participants with advanced melanoma.The study will involve initial administration of EDP1503 for a run-in perio...

Active, not recruiting
Melanoma
Melanoma (Skin)
Biological: EDP1503
Drug: Pembrolizumab

Phase 2

The University of Chicago
The University of Chicago

Chicago, Illinois, United States

treatment of adult subjects with completely treated high-risk ocular melanoma, as defined in eligibility criteria, without evidence of metas...

Active, not recruiting
Melanoma
Ocular Melanoma
Drug: Ipilimumab
Drug: Nivolumab

Phase 2

Suthee Rapisuwon

Chicago, Illinois, United States and 5 other locations

to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...

Active, not recruiting
Melanoma
Biological: Nivolumab
Biological: Nivolumab + Relatlimab Fixed Dose Combination

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Chicago, Illinois, United States and 171 other locations

and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...

Active, not recruiting
Melanoma
Other: Placebo
Biological: Nivolumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Chicago, Illinois, United States and 128 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems